ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.903,39
1,31%
S&P 500
5.996,66
1,00%
Dow Jones
43.487,83
0,78%
Euro vs US Dollar
1,03035
0,00%
Bitcoin
103.308,69
-0,78%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Revance Therapeutics Inc (RVNC)

  7. Revance Therapeutics Inc (RVNC) News

RVNC

Revance Therapeutics (RVNC)

Revance Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:RVNC
DatumZeitQuelleÜberschriftSymbolFirma
17/01/202514h15Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
16/01/202511h45PR Newswire (US)Revance Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNCNASDAQ:RVNCRevance Therapeutics Inc
13/01/202522h18Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
13/01/202514h44Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
13/01/202514h30PR Newswire (US)Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.NASDAQ:RVNCRevance Therapeutics Inc
13/01/202511h45PR Newswire (US)Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreNASDAQ:RVNCRevance Therapeutics Inc
10/01/202522h52Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RVNCRevance Therapeutics Inc
09/01/202511h45PR Newswire (US)The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNCNASDAQ:RVNCRevance Therapeutics Inc
06/01/202515h00Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
06/01/202515h00PR Newswire (US)Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in CashNASDAQ:RVNCRevance Therapeutics Inc
02/01/202522h45Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
02/01/202522h36Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
19/12/202415h00Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
12/12/202414h01Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:RVNCRevance Therapeutics Inc
12/12/202414h00PR Newswire (US)Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per shareNASDAQ:RVNCRevance Therapeutics Inc
12/12/202413h15Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:RVNCRevance Therapeutics Inc
12/12/202412h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
09/12/202423h16Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:RVNCRevance Therapeutics Inc
09/12/202415h24Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:RVNCRevance Therapeutics Inc
09/12/202415h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
09/12/202414h30PR Newswire (US)Crown Laboratories and Revance Enter into Amended and Restated Merger AgreementNASDAQ:RVNCRevance Therapeutics Inc
09/12/202414h30Business WireCrown Laboratories and Revance Enter into Amended and Restated Merger AgreementNASDAQ:RVNCRevance Therapeutics Inc
05/12/202422h23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
03/12/202414h27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
29/11/202412h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
26/11/202412h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
19/11/202422h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
19/11/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
07/11/202422h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
07/11/202422h05Business WireRevance Reports Third Quarter 2024 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:RVNC

Kürzlich von Ihnen besucht

HITB
AVTETH
AVT - Aventus
BOV
NBOV11
Nu Ibovespa B3 Br Classe...
GATE
EMPIREETH
Empire Token
ASE
ANDRO
Alpha Trust Andromeda In...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten